1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. Lyell Acquires ImmPACT Bio

M&A Deal Summary

Lyell Acquires ImmPACT Bio

On October 24, 2024, Lyell acquired life science company ImmPACT Bio

Acquisition Highlights
  • This is Lyell’s 1st transaction in the Life Science sector.
  • This is Lyell’s 1st transaction in the United States.
  • This is Lyell’s 1st transaction in California.

M&A Deal Summary
Date 2024-10-24
Target ImmPACT Bio
Sector Life Science
Buyer(s) Lyell
Deal Type Add-on Acquisition
Advisor(s) Cooley (Legal)

Target

ImmPACT Bio

West Hills, California, United States
ImmPACT Bio is a clinical-stage biotechnology company. ImmPACT’s lead program, IMPT-314, is a CD19/20-targeting chimeric antigen receptor (CAR) T-cell product candidate Lyell will continue developing for hematologic malignancies, including large B-cell lymphoma. IMPT-314 was designed to outperform the efficacy of approved CD19 CAR T-cell therapies via a dual-targeting CAR T-cell design and to improve CAR T-cell persistence by enriching for naïve and central memory T cells during manufacturing. ImmPACT Bio was founded in 2017 and is based in West Hills, California.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Lyell

South San Francisco, California, United States
Category Company
Founded 2018
Sector Life Science
Employees224
Revenue 85M USD (2022)
DESCRIPTION

Lyell is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies. Lyell’s product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness in order to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical response. Lyell was founded in 2018 and is based in South San Francisco, California.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2024 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal